Replies to post #53388 on Avid Bioservices Inc (CDMO)

[entdoc]

A Phase II trial evaluating T-DM1 for this use has completed patient enrollment, with interim data expected to be reported at the European Society of Medical Oncology (ESMO) meeting being held Oct. 8-12, 2010 in Milan, Italy. This trial compares T-DM1, given as a single agent, to Herceptinâ (trastuzumab) plus Taxotereâ (docetaxel).